SNYNF — Sanofi
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1121404 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 11,244,000,000 | 8,106,000,000 | 2,269,000,000 | 1,614,000,000 | 128,024,000,000 | 5,544,000,000 | 54,881,000,000 |
| Dec 2025 | 12,205,000,000 | 8,449,000,000 | 1,630,000,000 | -801,000,000 | 126,805,000,000 | 7,657,000,000 | 55,095,000,000 |
| Sep 2025 | 13,170,000,000 | 9,758,000,000 | 3,785,000,000 | 2,802,000,000 | 129,794,000,000 | 8,906,000,000 | 56,261,000,000 |
| Jun 2025 | 10,735,000,000 | 7,743,000,000 | 1,712,000,000 | 3,940,000,000 | 124,959,000,000 | 15,359,000,000 | 54,680,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$10,336,000,000
Investing CF
$-14,175,000,000
Financing CF
$-9,102,000,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.74
As of
2026-05-10
Yahoo Snapshot (yfinance, live)
Total Revenue
$47,353,999,360
EBITDA
$12,826,999,808
Free Cash Flow
$16,672,499,712
Enterprise Value
$121,443,909,632
Total Cash
$5,544,000,000
Total Debt
$20,021,000,192
Shares Out
1,196,884,513
Trailing EPS
$4.57
Book Value
$69.74
ROE
6.6%
ROA
4.7%
Div Yield
5.47%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 46,716,000,000 | 9,597,000,000 | 7,813,000,000 | 126,805,000,000 | 55,095,000,000 | — | 10,750,000,000 |
| Dec 2024 | 44,286,000,000 | 8,923,000,000 | 5,560,000,000 | 132,798,000,000 | 54,941,000,000 | — | 9,081,000,000 |
| Dec 2023 | 41,618,000,000 | 8,691,000,000 | 5,400,000,000 | 126,464,000,000 | 52,111,000,000 | — | 10,258,000,000 |
| Dec 2022 | 40,561,000,000 | 10,926,000,000 | 8,371,000,000 | 126,722,000,000 | 51,570,000,000 | — | 10,526,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$9.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.01T | $1133.00 | — |
| JNJ | JOHNSON & JOHNSON | $579.83B | $240.87 | — |
| ABBV | AbbVie Inc. | $402.35B | $227.73 | — |
| MRK | Merck & Co., Inc. | $294.03B | $119.05 | — |
| NVS | NOVARTIS AG | $292.07B | $153.07 | — |
News headlines (Yahoo Finance, 1h cache)
C-Path Reaffirms Commitment to Advancing Regulatory Science for Disease-Modifying Therapies in Type 1 Diabetes
2026-06-15 19:58 · Yahoo
Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight
2026-06-15 17:00 · Yahoo
Sanofi: Information concerning the total number of voting rights and shares – May 2026
2026-06-15 16:05 · Yahoo
AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus
2026-06-15 14:54 · Yahoo
Sanofi’s Tzield Approval Adds New Dimension To Endocrinology Story
2026-06-15 04:17 · Yahoo
Sanofi (ENXTPA:SAN) Stock After Mixed CIDP Trial Halt And Sarclisa EU Approval How Does Valuation Look Now
2026-06-14 20:06 · Yahoo
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
2026-06-12 22:09 · Yahoo
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
2026-06-12 21:13 · Yahoo
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Ann
2026-06-12 12:22 · Yahoo
Drug developers eye sport’s biggest stage as World Cup fever builds
2026-06-11 16:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.